Breast Cancer Companion Diagnostics to Surpass $1B by 2022

Press Releases

Breast Cancer Companion Diagnostics to Surpass $1B by 2022

May 30, 2018

WELLESLEY, Mass., May 30, 2018 -- The need for safer, more efficacious drugs and better diagnostic tools is driving growth in the global market for breast cancer diagnostics and drug technologies. An updated study by BCC Research forecasts this market to reach $21.8 billion by 2022 and examines it by breast cancer therapies, mammography, biopsy and companion diagnostics.

The worldwide incidence of breast cancer is gradually increasing, making it an attractive area of research and development. Drugs for breast cancer comprise a dynamic and growing global market. In addition, specific and effective diagnostic tools are needed for early diagnosis and treatment. From $18.2 billion in 2017, this market is projected to expand at a five-year compound annual growth rate (CAGR) of 3.6%, according to BCC Research’s updated report, Breast Cancer Diagnostics and Drug Technologies: Global Markets.

The breast cancer drugs segment is expected to reach $17.5 billion by 2022, with Roche predicted to account for more than half. Common detection techniques include diagnostic mammography and ultrasound followed by biopsy. Studies show that treatment is far more effective when the cancer is detected early.

Research Highlights

  • Growth in the global mammography market will be driven mainly by an increase in the female geriatric population.
  • The global breast biopsy market is projected to reach $1.4 million by 2022. North America dominated in 2017 with a 47.4% share.
  • The global breast cancer companion diagnostic test market is expected to surpass $1 billion by 2022. This growth is due to widespread acceptance of predictive diagnostics in North America and steady adoption in developing regions.

“Early treatment and detection have improved the five-year survival rate for women diagnosed with breast cancer to nearly 80%,” the report notes. “The prevalence of breast cancer is expected to reach 6.3 million by 2020, increasing at a CAGR of 3.9%. With the anticipated rise in the number of cases, breast cancer research and development requires attention from pharmaceutical firms.”

Increases in Healthcare Expenditure and Funding

Breast cancer is the second most common type of cancer. Governments from both developed and developing countries are actively engaged in designing and implementing programs to enhance awareness regarding breast cancer and the available diagnosis and treatment options. Increased funding from various government and nongovernment organizations drives the global breast cancer diagnostic and therapeutic market. Government entities around the world are encouraging the development of innovative technologies to reduce healthcare expenditures.

Breast Cancer Diagnostic and Drug Technologies: Global Markets( HLC106C )
Publish Date: May 2018    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email press@bccresearch.com or visit www.bccresearch.com/media to request access to our library of market research.